Resumes
Resumes
Vani Mocharla
View pageWork:
Siemens 2006 - 2012
Scientist
Scientist
Vani Mocharla Phones & Addresses
-
856 Muender Ave, Sunnyvale, CA 94086
-
705 Ramona Ave, Sunnyvale, CA 94087
-
1515 9Th St, Waco, TX 76706 (254) 753-7687 (254) 754-7363
-
1515 S 9Th St #314, Waco, TX 76706 (254) 754-7363
-
1406 9Th St, Waco, TX 76706
-
Los Angeles, CA
-
505 Harley Dr, Columbus, OH 43202
-
Santa Clara, CA
-
San Diego, CA
-
Forest Hills, NY
Work
Company:
Siemens 2006 to 2012
Position:
Scientist
Publications
Us Patents
Description Anti-Mitotic Agents Which Inhibit Tubulin Polymerization
View pageUS Patent:
6350777, Feb 26, 2002
Filed:
Dec 15, 2000
Appl. No.:
09/738394
Inventors:
Kevin G. Pinney - Hewitt TX
George R. Pettit - Paradise Valley AZ
Vani P. Mocharla - Waco TX
Maria del Pilar Mejia - Evanston IL
Anupama Shirali - Pune, IN
George R. Pettit - Paradise Valley AZ
Vani P. Mocharla - Waco TX
Maria del Pilar Mejia - Evanston IL
Anupama Shirali - Pune, IN
Assignee:
Baylor University
Arizona Disease Control Research Commission
Arizona Disease Control Research Commission
International Classification:
A61K 3134
US Classification:
514469, 514419, 514416, 514721, 549468, 549469, 548492, 548493, 568644, 568510
Abstract:
Methoxy and ethoxy substituted 3-aroyl-2-arylbenzo[b]thiophenes and benzo[b]thiophene analogues are described for use in inhibiting tubulin polymerization. The compounds use for treating tumor cells is also described. Additional aspects described here are certain diaryl ether benzo[b]thiophene derivatives. Also described are particular analogs derived from dihydronaphthalene which have proven particularly effective. Certain new benzofuran analogs are described, as well as certain sulfur oxide benzo[b]thiophene analogs. Important compounds described herein include the first nitrogen-containing derivatives of combretastatin. These include nitro, amino and azide combrdtastatin derivatives.
Tubulin Binding Ligands And Corresponding Prodrug Constructs
View pageUS Patent:
6593374, Jul 15, 2003
Filed:
Mar 12, 2001
Appl. No.:
09/804280
Inventors:
Kevin G. Pinney - Hewitt TX
Vani P. Mocharla - Waco TX
Zhi Chen - Hamden CT
Charles M. Garner - McGregor TX
Anjan Ghatak - Waco TX
James M. Dorsey - Waco TX
Vani P. Mocharla - Waco TX
Zhi Chen - Hamden CT
Charles M. Garner - McGregor TX
Anjan Ghatak - Waco TX
James M. Dorsey - Waco TX
Assignee:
Baylor University - Waco TX
International Classification:
A61K 31075
US Classification:
514721, 568633, 564443, 558197
Abstract:
A diverse set of tubulin binding ligands have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining arylâaryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates capable of demonstrating selective targeting and destruction of tumor cell vasculature.
Compositions And Methods For Use In Targeting Vascular Destruction
View pageUS Patent:
6956054, Oct 18, 2005
Filed:
Aug 14, 2002
Appl. No.:
10/218833
Inventors:
Ronald W. Pero - Arlington VT, US
David Sherris - Jamaica Plain MA, US
Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - West Haven CT, US
David Sherris - Jamaica Plain MA, US
Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - West Haven CT, US
Assignee:
Baylor University - Waco TX
OXiGENE, Inc. - Waltham MA
OXiGENE, Inc. - Waltham MA
International Classification:
A61K031/40
A61K031/38
A61K031/38
US Classification:
514419, 514415, 514443, 514733, 514731, 424600, 424601, 424602, 424603, 424604, 424605
Abstract:
Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.
Tubulin Binding Agents And Corresponding Prodrug Constructs
View pageUS Patent:
7001926, Feb 21, 2006
Filed:
Apr 1, 2003
Appl. No.:
10/404525
Inventors:
Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - San Diego CA, US
Zhi Chen - Hamden CT, US
Usha R. Ghatak, legal representative - West Bengal, IN
Mallinath Hadimani - Waco TX, US
Jimmy Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Oxford, GB
Joseph Prezioso - Boston MA, US
Vani P. Mocharla - San Diego CA, US
Zhi Chen - Hamden CT, US
Usha R. Ghatak, legal representative - West Bengal, IN
Mallinath Hadimani - Waco TX, US
Jimmy Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Oxford, GB
Joseph Prezioso - Boston MA, US
Assignee:
Oxigene, Inc. - Waltham MA
Baylor University - Waco TX
Baylor University - Waco TX
International Classification:
A61K 31/075
C07C 41/00
C07C 41/00
US Classification:
514721, 568633
Abstract:
A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
Tubulin Binding Ligands And Corresponding Prodrug Constructs
View pageUS Patent:
7091240, Aug 15, 2006
Filed:
Apr 29, 2003
Appl. No.:
10/425462
Inventors:
Kevin G. Pinney - Woodway TX, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - Hamden CT, US
Charles M. Garner - Waco TX, US
Mallinath Hadimani - Waco TX, US
Raymond Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Watlington, CA
Joseph Prezioso - Boston MA, US
Usha Ghatak, legal representative - Salt Lake City UT, US
Vani P. Mocharla - Waco TX, US
Zhi Chen - Hamden CT, US
Charles M. Garner - Waco TX, US
Mallinath Hadimani - Waco TX, US
Raymond Kessler - Sugarland TX, US
James M. Dorsey - Durham NC, US
Klaus Edvardsen - Klampenborg, DK
David J. Chaplin - Watlington, CA
Joseph Prezioso - Boston MA, US
Usha Ghatak, legal representative - Salt Lake City UT, US
Assignee:
Oxigene, Inc. - Watertown MA
Baylor University - Waco TX
Baylor University - Waco TX
International Classification:
A61K 31/34
C07D 307/93
C07D 307/93
US Classification:
514469, 549468
Abstract:
A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
Development Of Molecular Imaging Probes For Carbonic Anhydrase-Ix Using Click Chemistry
View pageUS Patent:
7829063, Nov 9, 2010
Filed:
Apr 7, 2008
Appl. No.:
12/099135
Inventors:
Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Dhanalakshmi Kasi - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Bing Wang - San Jose CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Brian A. Duclos - Kalamazoo MI, US
Kai Chen - Los Angeles CA, US
Wei Zhang - Los Angeles CA, US
Gang Chen - Los Angeles CA, US
Henry Clifton Padgett - Hermosa Beach CA, US
Farhad Karimi - Canton MA, US
Peter J. H. Scott - Marina-del-Ray CA, US
Zhiyong Gao - Los Angeles CA, US
Qianwa Liang - Hacienda Heights CA, US
Thomas Lee Collier - Perkasie PA, US
Tieming Zhao - Los Angeles CA, US
Chunfang Xia - Los Angeles CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Dhanalakshmi Kasi - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Bing Wang - San Jose CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Brian A. Duclos - Kalamazoo MI, US
Kai Chen - Los Angeles CA, US
Wei Zhang - Los Angeles CA, US
Gang Chen - Los Angeles CA, US
Henry Clifton Padgett - Hermosa Beach CA, US
Farhad Karimi - Canton MA, US
Peter J. H. Scott - Marina-del-Ray CA, US
Zhiyong Gao - Los Angeles CA, US
Qianwa Liang - Hacienda Heights CA, US
Thomas Lee Collier - Perkasie PA, US
Tieming Zhao - Los Angeles CA, US
Chunfang Xia - Los Angeles CA, US
Assignee:
Siemens Medical Solutions USA, Inc. - Malvern PA
International Classification:
A61K 51/00
C07D 343/00
C07D 343/00
US Classification:
424 111, 549 32
Abstract:
The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.
Nucleoside Based Proliferation Imaging Markers
View pageUS Patent:
7928210, Apr 19, 2011
Filed:
Mar 3, 2008
Appl. No.:
12/074538
Inventors:
Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Robert M Yeh - Culver City CA, US
Kai Chen - Los Angeles CA, US
Umesh Gangadharmath - Los Angeles CA, US
Brian Duclos - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Farhad Karimi - Canton MA, US
Henry C. Padgett - Hermosa Beach CA, US
Qianwa Liang - Hacienda Heights CA, US
Tieming Zhao - Los Angeles CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Robert M Yeh - Culver City CA, US
Kai Chen - Los Angeles CA, US
Umesh Gangadharmath - Los Angeles CA, US
Brian Duclos - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Farhad Karimi - Canton MA, US
Henry C. Padgett - Hermosa Beach CA, US
Qianwa Liang - Hacienda Heights CA, US
Tieming Zhao - Los Angeles CA, US
Assignee:
Siemens Medical Solutions USA, Inc. - Malvern PA
International Classification:
C07H 21/02
C07H 21/04
C07H 21/04
US Classification:
536 231, 536 253, 536 2532, 536 271, 536 2713, 536 281
Abstract:
Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation.
Achievement Of A High Therapeutic Index Through Molecular Imaging Guided Targeted Drug Treatment
View pageUS Patent:
8293206, Oct 23, 2012
Filed:
Jun 1, 2009
Appl. No.:
12/455346
Inventors:
Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Kai Chen - Rockville MD, US
Dhanalakshmi Kasi - Los Angeles CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Peter J. H. Scott - Ypsilanti MI, US
Gang Chen - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Kai Chen - Rockville MD, US
Dhanalakshmi Kasi - Los Angeles CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Peter J. H. Scott - Ypsilanti MI, US
Gang Chen - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Assignee:
Siemens Medical Solutions USA, Inc. - Malvern PA
International Classification:
A61M 36/14
A61K 39/00
A61K 39/00
US Classification:
424 169, 4241811
Abstract:
The present disclosure provides methods for treating cancer in a patient in need of such treatment, the method includes prequalifying a patient's therapeutic treatment by performing a molecular imaging procedure to the patient using a labeled biomarker specific for a cancer target at the tumor site; and administering a therapeutic effective amount of a compound comprising a targeting agent linked to a chemotherapeutic or a targeting agent linked to an antibody. Embodiments of the present invention also include compounds and compositions for using such methods.